Circumcision is a commonly performed surgical procedure both in childhood and in adults. Acute ischemia of the glans penis after circumcision is a rare but hazardous complication. If left untreated, it can lead to severe consequences such as blackish discolouration due to ischemia, necrosis, or rare organ loss.
View Article and Find Full Text PDFFollowing a 2015 conference on the future of continuing pharmacy education (CPE), the Accreditation Council for Pharmacy Education's Board of Directors ratified recommendations to address two key questions: (1) "What next steps should the profession take to ensure practitioner competence based on marketplace and regulatory changes in the next 10 to 15 years?" and (2) "How can the value of CPE be optimized over the next 10 to 15 years?" In this article, we describe how these recommendations have been addressed since the 2015 conference, highlighting advancements in technology and the adoption of continuing professional development, and describe future directions and additional opportunities to optimize CPE.
View Article and Find Full Text PDFIn response to a published national payer survey indicating striking needs for multistakeholder initiatives to increase biosimilar adoption, a focus workgroup meeting joining payers and providers was conducted in December 2019 in Boston, MA. Before the focus group meeting, a survey was sent to health care providers to collect perceptions about barriers to biosimilar adoption and gather input on best potential strategies for addressing these barriers. The focus group panel consisted of 5 managed care pharmacists and 3 physician experts in rheumatology, dermatology, and gastroenterology, representing large managed care organizations and health care systems in the Boston area.
View Article and Find Full Text PDFMultiple barriers exist for appropriate use of the proprotein convertase subtilisin/kexin type 9 enzyme inhibitors (PCSK9i) in patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) with inadequately controlled hypercholesterolemia despite standard therapies. Among these barriers, high payer rejection rates and inadequate prior authorization (PA) documentation by providers hinder optimal use of PCSK9i. To (a) identify and discuss provider and payer discordances on barriers to authorization and use of PCSK9i based on clinical and real-world evidence and (b) align understanding and application of clinical, cost, safety, and efficacy data of PCSK9i.
View Article and Find Full Text PDFBackground: The Biologics Price Competition and Innovation Act (BPCIA) of 2009, which included pathways for FDA approval of biosimilar products, was designed to promote more affordable, expanded patient access to biologic therapies. Achieving these BPCIA goals depends on overcoming formidable barriers to biosimilar adoption. Managed care and specialty pharmacy professionals are uniquely qualified to inform initiatives to address these barriers.
View Article and Find Full Text PDFJ Am Pharm Assoc (Wash)
March 2003
Objectives: To identify individuals in schools of pharmacy in the United States who are responsible for covering the topic of pain management in courses for doctor of pharmacy students and to describe how and at what depth pain management is covered in pharmacy school curricula.
Design: One-time qualitative assessment.
Setting: Schools of pharmacy in the United States.
J Am Pharm Assoc (Wash)
January 2003
OBJECTIVES To identify individuals in schools of pharmacy in the United States who are responsible for covering the topic of pain management in courses for doctor of pharmacy students and to describe how and at what depth pain management is covered in pharmacy school curricula. DESIGN One-time qualitative assessment. SETTING Schools of pharmacy in the United States.
View Article and Find Full Text PDF